Blue-Light Endoscope Trial Closed

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 5
Volume 4
Issue 5

RICHMOND, BC, Canada--Xillix Technologies Corp. has closed the North American multicenter clinical trial of its LIFE (lung imaging fluorescence endoscope)-Lung Imaging System that began in April, 1993.

RICHMOND, BC, Canada--Xillix Technologies Corp. has closed theNorth American multicenter clinical trial of its LIFE (lung imagingfluorescence endoscope)-Lung Imaging System that began in April,1993.

The system uses tissue autofluo-rescence to enhance the physician'sability to locate suspicious lung tissue for biopsy. By usingblue rather than conventional white light, the system can pickup subtle differences between precancerous or cancerous tissueand normal tissue, the company said.

Preliminary data showed a relative improvement of 161% in theability to identify suspicious tissue for moderate to severe dysplasiaor worse when the LIFE System was used as an adjunct to whitelight bronchoscopy versus white light bronchoscopy alone.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Related Content